Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Non2.0
Noni – Forschung
Überwiegend Mechanismus / Beobachtung
17 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Noni sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen randomisierten Studien, veröffentlicht 2004–2026 mit einer typischen Studiengröße von 81 Teilnehmenden.
Basierend auf 17 Studien · 9 RCTs · 369 Teilnehmende insgesamt
Konfidenz
Mittlere Konfidenz
Nach Outcome
Immune supportKeine überzeugende Evidenz beim Menschen für einen Nutzen für das Immunsystem; nur Surrogat-Antioxidansmarker in einer industriefinanzierten Studie · Unbekannt / unbelegt
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
8 Studien in den letzten 5 Jahren
200420152026
1Systematische Übersicht2024
Einfach gesagt: This review underscores the need for further research into Noni's anticancer properties, with the hope of stimulating additional studies and clinical trials to validate and expand upon these promising findings.
Kitic D, Miladinovic B, Randjelovic M, Szopa A, Seidel V, Prasher P, Sharma M, Fatima R, Arslan Ateşşahin D, Calina D, Sharifi-Rad J. · Phytotherapy research : PTR (2024)
The compiled studies highlight Noni's multifaceted role in cancer therapy, showcasing its various bioactive components and their modes of action.
This includes mechanisms such as apoptosis induction, cell cycle arrest, antiangiogenesis, and immune system modulation, demonstrating significant anticancer and chemopreventive potential.
The findings reinforce Noni's potential as a safe and effective option in cancer prevention and treatment.
Einfach gesagt: Confirmation in larger, prospectively registered trials with clinically adjudicated infection-related endpoints is warranted.
Shin SM, Park SH, Bae SG, Park EY, Lee JY, Kwon HY, La IJ, Youn SJ, Choi Y, Choi YE, Kim DH, Park SY, Moon C, Kim TY. · Nutrients (2026)
Adjusted between-group LS mean differences (95% CI) were +8.94 (-0.61, 18.50; p = 0.066) at E:T 50:1, +7.68 (-1.14, 16.50; p = 0.087) at 25:1, and +3.29 (-2.95, 9.54; p = 0.145) at 12.5:1, all favouring treatment but not reaching the conventional threshold for significance in the mITT/FAS.
Prespecified PPS sensitivity analyses reached significance at E:T 50:1 (+11.03; p = 0.025) and 25:1 (+9.94; p = 0.028).
The treatment group also showed greater increases in selected cytokines (IFN-γ, IL-2, IL-6, IL-10) relative to placebo.
Einfach gesagt: This review provides an overview of the bioactive components in noni and analyzes the in vitro and in vivo evidence regarding its bioactive compounds and their mechanisms, thus underscoring its potential as a natural intervention targeting multiple pathophysiological mechanisms for the treatment of SMD.
Li CH, Huang YX, Duan Y, Liu GP, Ai ZW, Ai ZF, Li J, Li SX. · Food & function (2025)
Studies indicate that noni and its bioactive components, such as scopoletin, quercetin, rutin, ursolic acid, and polysaccharides, exert beneficial effects on systemic metabolic disorder (SMD).
Einfach gesagt: This article stresses the multifaceted neuroprotective effects of noni and reasserts its therapeutic potential against neurodegenerative diseases.
Goel F, Garg VK. · Molecular neurobiology (2025)
Moreover, noni controls cell survival through the PI3K/Akt/mTOR and MAPK pathways, promoting neuronal resistance and anti-apoptosis.
Preclinical evidence is strong in showing the efficacy of noni against neurodegeneration, but clinical evidence is needed to ascertain its translational potential.
However, despite promising preclinical evidence highlighting noni's neuroprotective potential, a significant gap remains in its clinical validation underscoring the need for a comprehensive evaluation of current findings to guide future translational research.
Einfach gesagt: Although evidence of its beneficial effects is growing, further clinical studies and standardization of extracts are necessary to ensure its safe and effective use in medical practice.
Among these, antioxidant activity is particularly notable, with different extracts and isolated compounds demonstrating potent free radical scavenging capabilities.
Additionally, the antimicrobial potential against resistant bacteria, healing effects observed in animal models, and immunomodulatory properties further support the traditional therapeutic use of noni.
Moreover, the plant shows promise for applications in the formulation of pharmaceutical, cosmetic, and nutraceutical products.
Einfach gesagt: Two patients developed liver injury after noni-juice consumption — one required urgent liver transplantation after sub-acute hepatic failure.
Stadlbauer V, Fickert P, Lackner C, Schmerlaib J, Krisper P, Trauner M, Stauber RE · World J Gastroenterol (2005)
Two-case series of noni-associated hepatotoxicity
A 29-year-old man developed sub-acute hepatic failure after 1.5 L over 3 weeks and required liver transplantation
A 62-year-old woman had self-limited acute hepatitis after 2 L over 3 months
Einfach gesagt: A 24-year-old woman developed fulminant hepatitis after 4 weeks of noni juice taken for 'immune stimulation'; liver enzymes normalized after she stopped.
Single case report of fulminant hepatitis temporally linked to noni juice
Viral, metabolic and autoimmune hepatitis were excluded and biopsy indicated drug-induced toxicity, though the patient was concurrently on interferon beta-1a (a competing hepatotoxic exposure), weakening causal attribution to noni
Transaminases normalized within a month of stopping noni juice
Einfach gesagt: Noni juice reduced plasma superoxide anion radicals and lipid hydroperoxides in heavy smokers over 30 days — surrogate oxidative-stress markers only, in a manufacturer-conducted trial.
Wang MY, Lutfiyya MN, Weidenbacher-Hoper V, Anderson G, Su CX, West BJ · Chem Cent J (2009)
30-day randomized, double-blind, placebo-controlled trial in 285 heavy smokers
Reduced plasma superoxide anion radicals and lipid hydroperoxides vs placebo
Endpoints were surrogate oxidative-stress markers, not clinical or immune outcomes
Einfach gesagt: A manufacturer-conducted study reported no hepatotoxicity of freeze-dried noni puree in HepG2 cells or rats, concluding adverse liver effects are 'unlikely'.
West BJ, Su CX, Jensen CJ · J Toxicol Sci (2009)
In-vitro (HepG2) and subchronic oral toxicity test in Sprague-Dawley rats
No reduction in cell viability and no histopathological liver changes reported
NOAEL for freeze-dried puree reported as >6.86 g/kg